These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38589406)

  • 1. Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.
    Bai X; Attrill GH; Gide TN; Ferguson PM; Nahar KJ; Shang P; Vergara IA; Palendira U; da Silva IP; Carlino MS; Menzies AM; Long GV; Scolyer RA; Wilmott JS; Quek C
    Nat Commun; 2024 Apr; 15(1):3014. PubMed ID: 38589406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
    Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-Related Toxicity Among Adolescent and Young Adult with Melanoma as Compared with the Elderly.
    Darwin A; Skinner A; Reed DR; Tanvetyanon T
    J Adolesc Young Adult Oncol; 2022 Dec; 11(6):550-555. PubMed ID: 35100046
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of single cell and bulk RNA sequencing reveals the heterogeneity of melanoma tumor microenvironment and predicts the response of immunotherapy.
    Zhang Y; Zhang C; He J; Lai G; Li W; Zeng H; Zhong X; Xie B
    Inflamm Res; 2024 Aug; 73(8):1393-1409. PubMed ID: 38896289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
    Liu D; Yang X; Wu X
    Front Immunol; 2021; 12():663495. PubMed ID: 34025664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
    Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
    Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
    Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
    Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study.
    Liu R; Yang F; Yin JY; Liu YZ; Zhang W; Zhou HH
    Front Immunol; 2021; 12():685370. PubMed ID: 34220837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
    Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the single cell spatial immune landscapes of the melanoma microenvironment.
    Magrill J; Moldoveanu D; Gu J; Lajoie M; Watson IR
    Clin Exp Metastasis; 2024 Aug; 41(4):301-312. PubMed ID: 38217840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer.
    Ravensbergen CJ; Polack M; Roelands J; Crobach S; Putter H; Gelderblom H; Tollenaar RAEM; Mesker WE
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients.
    Petrova V; Groth C; Bitsch R; Arkhypov I; Simon SCS; Hetjens S; Müller V; Utikal J; Umansky V
    Front Immunol; 2023; 14():1065767. PubMed ID: 36860876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment.
    Liang X; Lin X; Lin Z; Lin W; Peng Z; Wei S
    Comput Biol Med; 2023 May; 158():106850. PubMed ID: 37031510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures.
    Han X; Lu H; Tang X; Zhao Y; Liu H
    Immun Inflamm Dis; 2022 Jan; 10(1):43-59. PubMed ID: 34582114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
    Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
    Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
    [No Abstract]   [Full Text] [Related]  

  • 17. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
    Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
    Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors.
    Park C; Jeong DY; Choi Y; Oh YJ; Kim J; Ryu J; Paeng K; Lee SH; Ock CY; Lee HY
    Front Immunol; 2022; 13():1038089. PubMed ID: 36660547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
    Kawashima S; Togashi Y
    Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.